

201 CTGCTTCGCG ATGTACGGGC CAGATATACG ^{5' end of hCMV promoter} CGTTGACATT GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC
 281 ATTAGTTCAT AGCCCATATA TGGAGTCCG ^{CMV enhancer region (5' end)} CGTTACATAA CTTACGGTAA ATGGCCCCGC TGGCTGACCG CCCAACGACC
 361 CCCGCCCATF GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAC
 441 TATTTACGGT AACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCC CCTATTGACG TCAATGACGG
 521 TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA TGGGACTTTC CTA^{CT}TGGCA GTACATCTAC GTATTAGTCA
 601 TCGCTATTAC CATGGTGATG CGGTTTGGC AGTACATCAA TGGGCGTGA TAGCGGTTG ACTCACGGGG ATTTCCAAGT
 681 CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC
 761 CCCATTGACG ^{CAAT} CAAATGGGCG GTAGGCGTGT ACGGTGGGAG ^{TATA} GTCTATATAA GCAGAGCTCT ^{3' end of hCMV promoter} CTGGCTAACT ^{Putative transcriptional start} AGAGAACCCA
 841 CTGCTTACTG GCTTATCGAA ^{T7 promoter/priming site} ATTAATACGA CTCACTATAG GGAGACCCAA GC TGG CTA GCG TTT AAA CTT AAG
 Trp Leu Ala Phe Lys Leu Lys
 914 CTT GGT ACC GAG CTC GGA TCC ACT AGT CCA GTG TGG TGG AAT TCT GCA GAT ATC CAG CAC AGT GGC
 Leu Gly Thr Glu Leu Gly Ser Thr Ser Pro Val Trp Trp Asn Ser Ala Asp Ile Gln His Ser Gly
 980 GGC CGC TCG AGT CTA GAG GGC CCG CGG TTC GAA GGT AAG CCT ATC CCT AAC CCT CTC CTC GGT CTC
 Gly Arg Ser Ser Leu Glu Gly Pro Arg Phe Glu Gly Lys Pro Ile Pro Asn Pro Leu Leu Gly Leu
 1046 GAT TCT ACG CGT ACC GGT CAT CAT CAC CAT CAC CAT TGA GTTTAA ACCCGCTGAT CAGCCTCGAC ^{BGH}
 Asp Ser Thr Arg Thr Gly His His His His His His ***
 1111 TGTGCCTTCT ^{Reverse priming site} AGTTGCCAGC CATCTGTTGT TTGCCCTCC CCCGTGCCTT CCTTGACCCT GGAAGGTGCC ACTCCCCTG
 1191 TCCTTTCCTA ^{BGH polyadenylation signal} ATAAAATGAG GAAATGTCAT CGCATTGTCT GAGTAGGTGT CATTCTATTC TGGGGGGTGG GGTGGGGCAG